Cargando…

Initiating Insulin Therapy in Type 2 Diabetic Patients Failing on Oral Hypoglycemic Agents: Basal or prandial insulin? The APOLLO trial and beyond

Detalles Bibliográficos
Autores principales:	Bretzel, Reinhard G., Eckhard, Michael, Landgraf, Wolfgang, Owens, David R., Linn, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Diabetes Progression, Prevention, and Treatment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811479/ https://www.ncbi.nlm.nih.gov/pubmed/19875561 http://dx.doi.org/10.2337/dc09-S319

Ejemplares similares

Insulin Therapy for Type 2 Diabetes
por: Swinnen, Sanne G., et al.
Publicado: (2009)

Where Does Insulin Resistance Start?: The brain
por: Pagotto, Uberto
Publicado: (2009)

Early Insulin Treatment in Type 2 Diabetes: What are the pros?
por: Meneghini, Luigi F.
Publicado: (2009)

Early Insulin Use in Type 2 Diabetes: What are the cons?
por: Chiasson, Jean-Louis
Publicado: (2009)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Viewpoints on the Way to the Consensus Session: Where does insulin resistance start? The adipose tissue
por: Iozzo, Patricia
Publicado: (2009)

Viewpoints on the Way to a Consensus Session: Where does insulin resistance start? The liver
por: Perseghin, Gianluca
Publicado: (2009)

Pivotal Role of Timely Basal Insulin Replacement After Metformin Failure in Sustaining Long-Term Blood Glucose Control at a Target in Type 2 Diabetes
por: Bolli, Geremia B., et al.
Publicado: (2011)

SAT-LB026 Basal-Prandial Insulin versus Basal-Sliding-Scale Insulin in the Management of Hyperglycemia in Non-Critically Ill Hospitalized Patients
por: Malkhasyan, Victoria, et al.
Publicado: (2019)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Goals of Treatment for Type 2 Diabetes: β-Cell preservation for glycemic control
por: Marchetti, Piero, et al.
Publicado: (2009)

β-Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults
por: Cernea, Simona, et al.
Publicado: (2009)

Changing the Treatment Paradigm for Type 2 Diabetes
por: Del Prato, Stefano, et al.
Publicado: (2009)

Target for Glycemic Control: Concentrating on glucose
por: Monnier, Louis, et al.
Publicado: (2009)

Defining and Characterizing the Progression of Type 2 Diabetes
por: Fonseca, Vivian A.
Publicado: (2009)

Bile Acids and Metabolic Regulation: Mechanisms and clinical responses to bile acid sequestration
por: Staels, Bart, et al.
Publicado: (2009)

Combined Pharmacologic/Nonpharmacologic Intervention in Individuals at High Risk of Developing Type 2 Diabetes: Pro pharmacologic therapy
por: Garber, Alan J.
Publicado: (2009)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Antioxidant Anti-Inflammatory Treatment in Type 2 Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2009)

Telemedical Artificial Pancreas: PARIS (Páncreas Artificial Telemédico Inteligente) research project
por: de Leiva, Alberto, et al.
Publicado: (2009)

Self-Monitoring of Blood Glucose as Part of the Integral Care of Type 2 Diabetes
por: Boutati, Eleni I., et al.
Publicado: (2009)

Nonpharmacologic Therapy and Exercise in the Prevention of Type 2 Diabetes
por: Tuomilehto, Jaakko
Publicado: (2009)

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
por: Lebovitz, Harold E.
Publicado: (2011)

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment
por: Gallwitz, Baptist, et al.
Publicado: (2013)

Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes
por: Bajaj, Harpreet S, et al.
Publicado: (2023)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

Suspension of basal insulin to avoid hypoglycemia in type 1 diabetes treated with insulin pump
por: Boronat, Mauro, et al.
Publicado: (2015)

Recombinant Human Insulins – Clinical Efficacy and Safety in Diabetes Therapy
por: Landgraf, Wolfgang, et al.
Publicado: (2016)

Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices
por: El-Laboudi, Ahmed H., et al.
Publicado: (2015)

Prolonged Hypoglycemic Effect Due to Intentional Massive Insulin Glargine Overdose
por: Gill, Kirit S, et al.
Publicado: (2021)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Basal Insulin Inadequacy versus Failure – Using Appropriate Terminology
por: Kalra, Sanjay, et al.
Publicado: (2015)

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes
por: Jain, S M, et al.
Publicado: (2010)

Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin
por: Santeusanio, Andrew D., et al.
Publicado: (2018)

ODP238 RELATIONSHIP BETWEEN BODY COMPOSITION, POST PRANDIAL GLUCOSE AND INSULIN FOR EARLY PREDICTION OF TYPE 2 DIABETES AND CARDIOVASCULAR RISK.
por: Moya, Elena Amoroso, et al.
Publicado: (2022)

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance
por: Doder, Zoran, et al.
Publicado: (2015)

An Uncommon Case of Recurrent Hypoglycemic Episodes in a Healthy Non-diabetic Male: Insulin Autoimmune Syndrome
por: Dhaliwal, Kanwarpal K, et al.
Publicado: (2023)

MON-663 Prandial Insulin Dosing Based on Carbohydrate Content Does Not Significantly Improve Glycemic Control in Hospitalized Patients with Diabetes
por: Goel, Heenam, et al.
Publicado: (2020)

A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study
por: Ito, Hiroyuki, et al.
Publicado: (2018)

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
por: Bergenstal, R. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2amvo2ln2bnv8h3id3ku898n1h